Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from BetterLife Pharma ( (TSE:BETR) ).
BetterLife Pharma has appointed André Beaudry as Corporate Advisor, leveraging his extensive experience in fundraising and governance to support the company’s strategic goals. This appointment is expected to enhance BetterLife’s efforts to bring its non-hallucinogenic compound, BETR-001, to human clinical trials, potentially impacting the treatment of various psychiatric and neurological disorders.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. Their primary products include BETR-001, a non-hallucinogenic LSD derivative, and BETR-002, based on honokiol, both in preclinical and IND-enabling studies. The company also owns a drug candidate for viral infections and is seeking strategic alternatives for its development.
YTD Price Performance: -20.0%
Average Trading Volume: 16,895
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.18M
For an in-depth examination of BETR stock, go to TipRanks’ Stock Analysis page.